The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma

被引:32
|
作者
Lu, Hongsheng [1 ]
Yang, Zhaohui [1 ]
Zhang, Hui [1 ]
Gan, Meifu [2 ]
Zhou, Tao [2 ]
Wang, Siling [1 ]
机构
[1] Taizhou Enze Med Grp, Taizhou Cent Hosp, Dept Pathol, Taizhou 318000, Zhejiang, Peoples R China
[2] Taizhou Enze Med Grp, Taizhou Hosp, Dept Pathol, Linhai 317000, Peoples R China
关键词
clear cell renal cell carcinoma; matrix metalloproteinase 7; tissue inhibitor of matrix metalloproteinases 2; prognosis; tissue microarray; CANCER; INVASION; POLYMORPHISMS; PROTEASES;
D O I
10.3892/etm.2012.859
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Renal cell carcinoma (RCC) is one of the most common malignant neoplasms in the urinary system, and has a high frequency of local invasion and distant metastasis. This study assessed the expression and clinical significance of matrix metalloproteinase 7 (MMP-7) and tissue inhibitor of matrix metalloproteinases 2 (TIMP-2) in human clear cell renal cell carcinoma (CCRCC) by tissue microarray, immunohistochemistry and RT-PCR analysis. The expression of MMP-7 in CCRCC tissues was significantly higher compared with that in the control group (CG) and TIMP-2 expression in CCRCC, by contrast, was lower compared with that in the CG. The expression of MMP-7 and TIMP-2 in the CCRCC tissues was significantly correlated with the pathological grade and clinical stage. Log-rank analyses indicated that upregulation of MMP-7 and downregulation of TIMP-2 expression may occur during the progression of CCRCC, and Cox multivariate survival rate analysis demonstrated that there was also a positive correlation between the pathological grade, clinical stage, MMP-7 expression and survival rate. Thus, MMP-7 is an independent prognostic factor and MMP-7 and TIMP-2 may serve as useful molecular markers for evaluating prognosis in CCRCC patients.
引用
收藏
页码:890 / 896
页数:7
相关论文
共 50 条
  • [1] Expression and Concentration of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in Laryngeal Squamous Cell Carcinoma
    Matulka, Marlena
    Konopka, Aneta
    Mroczko, Barbara
    Pryczynicz, Anna
    Kemona, Andrzej
    Groblewska, Magdalena
    Sieskiewicz, Andrzej
    Olszewska, Ewa
    DISEASE MARKERS, 2019, 2019
  • [2] Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma
    Sumi, T
    Nakatani, T
    Yoshida, H
    Hyun, Y
    Yasui, T
    Matsumoto, Y
    Nakagawa, E
    Sugimura, K
    Kawashima, H
    Ishiko, O
    ONCOLOGY REPORTS, 2003, 10 (03) : 567 - 570
  • [3] Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma
    Zhen-kui Qiao
    Yan-long Li
    Hong-tao Lu
    Ke-liang Wang
    Wan-hai Xu
    World Journal of Surgical Oncology, 11
  • [4] Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma
    Qiao, Zhen-kui
    Li, Yan-long
    Lu, Hong-tao
    Wang, Ke-liang
    Xu, Wan-hai
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2013, 11
  • [5] Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder
    Hara, I
    Miyake, H
    Hara, S
    Arakawa, S
    Kamidono, S
    JOURNAL OF UROLOGY, 2001, 165 (05): : 1769 - 1772
  • [6] Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma
    Charous, SJ
    Stricklin, GP
    Nanney, LB
    Netterville, JL
    Burkey, BB
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1997, 106 (04): : 271 - 278
  • [7] Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma
    Kawata, Nozomu
    Nagane, Yusuke
    Hirakata, Hitoshi
    Ichinose, Taketo
    Okada, Yasuhiro
    Yamaguchi, Kenya
    Takahashi, Satoru
    UROLOGY, 2007, 69 (06) : 1049 - 1053
  • [8] Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma
    Gao, ZB
    Duan, YQ
    Zhang, L
    Chen, DW
    Ding, PT
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2005, 16 (04) : 599 - 603
  • [9] Expression of matrix metalloproteinases in gastric carcinoma and possibility of clinical application of matrix metalloproteinase inhibitor in vivo
    Otani, Y
    Kubota, T
    Sakurai, Y
    Igarashi, N
    Yokoyama, T
    Kimata, M
    Wada, N
    Kameyama, K
    Kumai, K
    Okada, Y
    Kitajima, M
    INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 : 541 - 543
  • [10] Clinical significance of tissue inhibitor of metalloproteinase and matrix metalloproteinase mRNA expression in thymoma
    Yukiue, H
    Sasaki, H
    Kobayashi, Y
    Nakashima, Y
    Moriyama, S
    Yano, M
    Kaji, M
    Kiriyama, M
    Fukai, I
    Yamakawa, Y
    Fujii, Y
    JOURNAL OF SURGICAL RESEARCH, 2003, 109 (02) : 86 - 91